Atavistik Bio Announces $60 Million Series A Financing To Advance Genetically-Validated Targets In Metabolic Diseases And Cancer
Amount Raised
$60 Million
Round Type
Series A
CambridgeBiotechnologySoftwareHealth CareScience And EngineeringDescription
Atavistik Bio (“Atavistik”, “Company”), a pre-clinical biotechnology company pioneering the identification of metabolite-protein interactions that have the potential to lead to the discovery and development of first-in-class drug candidates powered by distinct allosteric control mechanisms, announced today that the Company had completed a $60 million Series A financing round. The financing was led by The Column Group and joined by Lux Capital, and Nextech Invest, Ltd.
Quick answer
Atavistik Bio raised $60 Million in a Series A round, dated August 24, 2021. Atavistik Bio is based in Cambridge, Massachusetts, United States.
- How much did Atavistik Bio raise?
- Atavistik Bio raised $60 Million in a Series A round on August 24, 2021.
- What does Atavistik Bio do?
- Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology.
- Where is Atavistik Bio based and how big is it?
- Atavistik Bio is based in Cambridge, Massachusetts, United States. Fundz records about 38 employees.
- Who are the decision-makers at Atavistik Bio?
- Fundz holds 1 contact at Atavistik Bio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Atavistik Bio that raised within 45 days of this round, from Fundz verified event records.
- Exscientia raised $510M (Post-IPO Equity) on October 5, 2021.
- PBS Biotech raised $10M (Funding Round) on August 16, 2021.
- PMGC Holdings Inc. raised $732K (Seed) on October 1, 2021.
- PMGC Holdings Inc. raised $139K (Pre-Seed) on October 1, 2021.
- Envisagenics raised an undisclosed amount (Series A) on September 29, 2021.
- Athos Therapeutics, Inc. raised $13M on September 28, 2021.
Who to call at Atavistik Bio, and when
A new round usually means Atavistik Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Atavistik Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Atavistik Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Atavistik Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Atavistik Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAtavistik Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.